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Synopsis 26 
Objectives: To assess antimicrobial susceptibility for 14 agents tested against 6001 invasive 27 
isolates of Streptococcus pneumoniae cultured from invasive patient samples from 2011 to 2015 28 
as a part of the annual SAVE study. 29 
Methods: Isolates of S. pneumoniae were tested using the standard CLSI broth microdilution 30 
method (M07-A10, 2015) with MICs interpreted by CLSI M100 27th Edition (2017) MIC 31 
breakpoints. 32 
Results: From 2011 to 2015, small but significant increases (P<0.05) in percent susceptibility 33 
for penicillin (interpreted by all three CLSI MIC breakpoint criteria) (1.7 – 3.2%), clindamycin 34 
(3.1%) and ceftriaxone (interpreted by non-meningitis and meningitis CLSI MIC breakpoint 35 
criteria) (1.1 – 1.5%) were observed.  Susceptibility rates for clarithromycin and other commonly 36 
tested antimicrobial agents remained unchanged (P>0.05) over the five-year period.  Isolates 37 
with a MDR phenotype (resistance to three or more antimicrobial agent classes) decreased 38 
significantly (P <0.001) from 8.5% in 2011 to 5.6% in 2015.  Antimicrobial susceptiblity rates 39 
were not generally associated (P>0.05) with patient gender (exception: clarithromycin) but were 40 
associated (P<0.05) with patient age (chloramphenicol and clindamycin) or specimen source 41 
(penicillin, doxycycline, trimethoprim/sulfamethoxazole and clindamycin), as well as geographic 42 
location in Canada and concurrent resistance to penicillin or clarithromycin. 43 
Conclusions: The in vitro susceptibility of invasive isolates of S. pneumoniae in Canada 44 
increased to penicillin, clindamycin and ceftriaxone from 2011 to 2015 coincident with a 45 
significant decrease in MDR phenotypes.  46 
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Introduction 47 
Streptococcus pneumoniae is a leading cause of both invasive (e.g., bacteremia, meningitis) and 48 
non-invasive (e.g., pneumonia, otitis media) infections.1  Invasive pneumococcal disease (IPD) 49 
produces substantial patient morbidity and mortality, particularly among the very young (<5 50 
years), the elderly (≥65 years) and immunocompromised individuals.  In addition to the 51 
aforementioned risk factors for IPD, both carriage of, and infection with, antimicrobial-resistant 52 
S. pneumoniae is associated with previous antimicrobial use, institutionalization, and community 53 
or household exposure to antimicrobial-resistant isolates.2  Resistance arising following previous 54 
antimicrobial use is more dependent on the time elapsed since the last antimicrobial exposure 55 
rather than on the duration of therapy; the association between elapsed time and resistance was 56 
stronger for macrolides than other antimicrobial classes.2 57 
In patients with pneumococcal infection, particularly IPD, adequate antimicrobial therapy 58 
reduces morbidity and mortality, particularly when administered early in the course of disease.2  59 
The success of empiric antimicrobial therapy is continuously challenged by the threat of 60 
increasing antimicrobial resistance, serious adverse events, and collateral damage to patients’ 61 
colonizing flora.  The development of new antimicrobial agents with novel mechanisms of action 62 
and attempting to minimize the use of currently available agents through antimicrobial 63 
stewardship are two important strategies intended to subvert the spread of antimicrobial 64 
resistance. 65 
Vaccination is a proven means of reducing the incidence of IPD and antimicrobial 66 
resistance associated with serotypes included in the vaccine by reducing the transmission of 67 
resistant isolates.1,3-7  In June 2001, the 7-valent (4, 6B, 9V, 14, 18C, 19F, 23F) conjugate 68 
vaccine (PCV-7) was licensed for use in Canada and universal infant (children <2 years of age) 69 
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PCV-7 immunization programs were introduced in all Canadian provinces and territories 70 
between 2002 and 2006.1  As anticipated, the Canadian Immunization Monitoring Program, 71 
Active (IMPACT) reported a significant decrease in the number of cases of IPD between 2000 72 
and 2007 (a 48% decrease overall and 56% in children <5 years old)1 with the greatest decreases 73 
in incidence of IPD, and rates of antimicrobial resistance, occurring in children <2 years of 74 
age.1,3,4  At the same time, increases in non-vaccine serotypes (e.g., 19A) as causes of IPD and 75 
sources of antimicrobial resistance were observed and offset some of the reductions in PCV-7 76 
serotypes.1,5  Bettinger et al. reported that although the absolute number of reported IPD cases 77 
caused by serotypes in PCV-7 decreased 87.5%, overall the proportion of penicillin-resistant 78 
isolates remained unchanged at 17% and cefotaxime/ceftriaxone resistance remained unchanged 79 
at 2% annually.1  Subsequently, in 2010, a 13-valent polyvalent conjugate vaccine (PCV-13) 80 
targeting additional serotypes (1, 3, 5, 6A, 7F, 19A) was introduced in Canada and by mid-2011, 81 
all Canadian provinces and territories had incorporated PCV-13 into their routine immunization 82 
schedule.  Prior to PCV-13 introduction in Canada, Adam et al. reported that 54.3% of 83 
circulating serotypes causing IPD in 2007-2009 would be covered by PCV-13.6  Demczuk et al. 84 
later reported that from 2010 to 2014, PCV-13 serotypes declined in Canada, overall, from 55% 85 
of the isolates in 2010 to 43% in 2012 to 31% in 2014; by patient age, PCV serotype reductions 86 
were from 54 to 43% for children aged ≥5 years, from 66 to 41% for children <5 years old and 87 
from 63 to 42% for children aged <2 years.7,8  The rate of decrease in IPD serotypes in children 88 
following the introduction of PCV-13 was less dramatic than that observed for PCV-7 over a 89 
comparable time period.7  Serotype 22F has been the most common replacement serotype 90 
following use of PCV-13, increasing from 7% to 11%.8  Similar results have been observed in 91 
the United States for children <5 years of age where the use of PCV-7 and PCV-13 has also been 92 
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widespread; they observed a 90% decline in IPD in children <5 years of age and a 50% decline 93 
in adults between 1998 and 2015.9  As a result of the use of PCV-7 and PCV-13 in Canada, the 94 
overall incidence of IPD decreased from 9.8 to 8.9 cases per 100 000 population between 2009 95 
and 2014.  In 2014 in Canada, rates of IPD were highest in infants <1 year of age (16.9 cases per 96 
100 000 population), children 1-4 years of age (11.0 cases per 100 000 population), and in 97 
patients 60 years of age and older (21.5 cases per 100 000 population.10,11 98 
Despite the availability and use of pneumococcal conjugate vaccines in Canada, invasive 99 
infections continue to occur.  Therefore, access to current antimicrobial surveillance data such as 100 
that generated by the ongoing SAVE study in Canada remains important to clinicians, 101 
antimicrobial stewardship programs, infection control practitioners, antimicrobial formulary 102 
committees, clinical laboratory scientists, governments, academic scientists involved in drug 103 
discovery and the pharmaceutical industry as this data can improve the delivery of effective 104 
antimicrobial therapy (reducing discordant empiric therapy that results in increased rates of 105 
morbidity and mortality), determine the impact of immunization programs, provide the impetus 106 
to revise empiric therapy guidelines and help to prioritize future antimicrobial agent development 107 
agendas.2  The SAVE study is an annual surveillance program that collects and characterizes 108 
invasive isolates of S. pneumoniae submitted by select provincial public health and hospital 109 
laboratories across Canada.  In the current study, invasive isolates of S. pneumoniae collected 110 
from 2011 to 2015, inclusive, by the SAVE study were tested for their susceptibilities to a panel 111 
of 14 antimicrobial agents using the standard CLSI broth microdilution method.12,13  Because 112 
comparative statistical analyses of factors associated with antimicrobial resistance have not been 113 
extensively performed using Canadian pneumococcal isolates, data from the SAVE study were 114 
also analyzed to evaluate the activities of several anti-pneumococcal agents on the basis of 115 
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factors such as patient age, patient gender, isolate specimen source, geographic region and MIC 116 
interpretative category for penicillin and clarithromycin. 117 
 118 
Materials and methods 119 
Bacterial isolates 120 
From January 2011 to December 2015, S. pneumoniae isolated from sterile body sites by 121 
participating Canadian provincial public health and hospital laboratories were forwarded to the 122 
Public Health Agency of Canada-National Microbiology Laboratory (PHAC-NML) in Winnipeg, 123 
Canada.  As part of an ongoing collaboration between the Canadian Antimicrobial Resistance 124 
Alliance (CARA) and PHAC-NML, PHAC-NML forwarded their collection of invasive isolates 125 
of S. pneumoniae eight provincial public health laboratories (Saskatchewan, Manitoba, Ontario, 126 
Quebec, Nova Scotia, Prince Edward Island, Newfoundland and Labrador, and a portion of 127 
isolates collected from New Brunswick) to CARA for antimicrobial susceptibility testing.  For 128 
the SAVE study, regional analysis were conducted as Western (Saskatchewan and Manitoba, 129 
n=1352), Central (Ontario and Quebec, n=4107) and Eastern (New Brunswick, Nova Scotia, 130 
Prince Edward Island, and Newfoundland and Labrador, n=748). 131 
In total, 6207 invasive isolates of S. pneumoniae collected as part of the SAVE study 132 
between 2011 and 2015 were forwarded to the CARA for antimicrobial susceptibility testing.  133 
Patient gender and age information was available for 5980 (96.3%) and 6072 (97.8%) of the 134 
isolates.  The annual numbers of isolates were: 1379 isolates from 2011, 1285 from 2012, 1138 135 
from 2013, 1210 from 2014, and 1195 from 2015. 136 
Antimicrobial susceptibility testing 137 
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Antimicrobial susceptibility testing was performed in the Department of Clinical Microbiology 138 
at the Winnipeg Health Sciences Centre using the standard CLSI broth microdilution method12,13 139 
with custom-designed, in-house prepared, 96-well microtitre panels containing doubling-140 
dilutions of antimicrobial agents in cation-adjusted Mueller-Hinton broth supplemented to a final 141 
concentration of 4% lysed horse blood.  All isolates were tested against penicillin, ceftriaxone, 142 
cefuroxime, clarithromycin, clindamycin, telithromycin, levofloxacin, moxifloxacin, linezolid, 143 
trimethoprim/sulfamethoxazole, doxycycline, tigecycline, chloramphenicol and vancomycin.  144 
MICs were interpreted as susceptible, intermediate or resistant using CLSI MIC breakpoints for 145 
all antimicrobial agents except tigecycline for which FDA MIC breakpoints were used 146 
(susceptible, ≤0.06 mg/L).14  MDR was defined as resistance to three or more antimicrobial 147 
agents selected as antimicrobial class markers (penicillin, clarithromycin, clindamycin, 148 
doxycycline, levofloxacin, trimethoprim/sulfamethoxazole and chloramphenicol).  In MDR 149 
calculations, penicillin resistance was defined using the CLSI breakpoint for oral penicillin V 150 
(MIC, ≥2 mg/L).13  Of the 6207 invasive isolates of S. pneumoniae received by CARA for 151 
antimicrobial susceptibility testing, complete susceptibility profiles for all 14 antimicrobial 152 
agents were generated for 6001 isolates; the remaining 206 isolates failed to grow or generated 153 
incomplete susceptibility profiles.  The number of isolates with complete antimicrobial 154 
susceptibility testing profiles per year was 1362 isolates in 2011, 1230 isolates in 2012, 1099 155 
isolates in 2013, 1159 isolates in 2014 and 1151 isolates in 2015. 156 
Statistical analysis 157 
Antimicrobial susceptibility rates between 2011 and 2015 and the associations between patient 158 
demographic or isolate factors and resistance to antimicrobial agents were assessed for 159 
statistically significant differences (P <0.05) using the 2-tailed Chi-square test. 160 
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 161 
Results 162 
From 2011 to 2015, small but significant increases (P<0.05) in percent susceptibility for 163 
penicillin (by all three MIC breakpoint criteria) (1.7 – 3.2%), clindamycin (3.1% increase) and 164 
ceftriaxone (by non-meningitis and meningitis MIC breakpoint criteria) (1.1 – 1.5% increase) 165 
were observed for invasive isolates of S. pneumoniae included in the SAVE study (Table 1).  166 
Susceptibility rates for all other antimicrobial agents tested remained unchanged (P>0.05) over 167 
the five-year period/ (Table 1).  In the clarithromycin subset analysis, significant differences (P 168 
<0.05) in the prevalence of putative mef[A] (i.e., M phenotype/efflux/low-level macrolide 169 
resistance; MICs of 1-32 mg/L; n=1157 [19.3% of all isolates]) and putative erm[B] (i.e., target 170 
site methylation/high-level macrolide resistance; MICs of ≥64 mg/L; n=240 [4.0% of all 171 
isolates]) phenotypes were not identified across the five-year period from 2011 to 2015 (data not 172 
shown)15 173 
The majority (71.5%; 4289/6001) of all isolates of invasive S. pneumoniae tested from 2011 to 174 
2015 were pan-susceptible to the panel of seven antimicrobial agents used in MDR analysis (Table 2).  175 
Of isolates demonstrating resistance to at least one antimicrobial agent, 62.1% (1064/1712) were 176 
resistant to only a single antimicrobial agent.  A MDR phenotype was demonstrated by 6.2% 177 
(372/6001) of all isolates tested.  The most common MDR phenotypes were concurrent resistance to 178 
clarithromycin, doxycycline and clindamycin (n=150; 40.3% of MDR isolates), concurrent resistance 179 
to clarithromycin, doxycycline, clindamycin, penicillin and trimethoprim/sulfamethoxazole (n=110; 180 
29.6% of MDR isolates) and concurrent resistance to clarithromycin, doxycycline, clindamycin and 181 
trimethoprim/sulfamethoxazole (n=18; 4.8% of MDR isolates) (as described elsewhere in this 182 
supplement).16  The rank order of frequency of resistance to specific antimicrobial agent classes 183 
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among MDR isolates of invasive S. pneumoniae was: clarithromycin > doxycycline ≈ clindamycin > 184 
trimethoprim/sulfamethoxazole ≈ penicillin >> chloramphenicol > levofloxacin (Table 2).  The rate of 185 
MDR among invasive isolates of S. pneumoniae decreased significantly (P <0.001) from 8.5% in 2011 186 
to 5.6% 2015, with the lowest rates seen during 2014 at 3.9%. 187 
Rates of antimicrobial resistance in invasive isolates of S. pneumoniae were significantly 188 
associated with patient age for chloramphenicol and clindamycin (P <0.05) and approached 189 
clinical significance for penicillin (P=0.057) (Table 3).  The penicillin resistance rates were 190 
highest (4.3%) and the chloramphenicol resistance rates were lowest (0.6%) among children less 191 
than 18 years of age.  Clindamycin resistance rates were higher for children less than 18 years of 192 
age and adults greater than 64 years of age compared to patients in the 18 to 64 year age 193 
category.  None of the other agents (clarithromycin, doxycycline and 194 
trimethoprim/sulfamethoxazole) demonstrated a significant association with patient age.  Patient 195 
gender was associated with resistance to clarithromycin and approached clinical significance for 196 
penicillin (P=0.075).  Specimen source was associated with resistance for all antimicrobial 197 
agents except clarithromycin and chloramphenicol.  Blood isolates generally had the lowest 198 
percent resistance rates and sterile body fluids (other than blood and cerebrospinal fluid) had the 199 
highest percent resistance rates.  Geographic region was also associated with resistance for all 200 
antimicrobial agents except clarithromycin and clindamycin, although the results approached 201 
signficance for these agents.  Resistance to penicillin and trimethoprim/sulfamethoxazole was 202 
more common among isolates from western and eastern Canada than for isolates from central 203 
Canada while resistance to chloramphenicol was highest in central Canada.  Resistance to 204 
doxycyline was more common among isolates from central and eastern Canada than from the 205 
western region.  Penicillin resistance and clarithromycin resistance were associated with each 206 
11 
 
other and with resistance to other antimicrobial agents (doxycycline, 207 
trimethoprim/sulfamethoxazole, chloramphenicol and clindamycin). 208 
 209 
Discussion 210 
Increases in antimicrobial resistance in S. pneumoniae is the result of the expansion of successful 211 
clones as well as the introduction of new clonal types.17-21  Previous observations provide strong 212 
evidence that the spread of penicillin-, macrolide-, trimethoprim/sulfamethoxazole-, 213 
fluoroquinolone-resistant and MDR S. pneumoniae is often driven by the dissemination of a few 214 
successful clones and that the use of non-fluoroquinolone antimicrobials (β-lactams, macrolides 215 
and trimethoprim/sulfamethoxazole) may lead to resistance to all three antimicrobial classes, 216 
given the propensity for these resistances to associate in clinical isolates.17-19,22  Given that PCV-217 
7 included serotypes that were frequently associated with non-susceptibility to penicillin and 218 
other antimicrobial agents, its use facilitated changes in the epidemiology of antimicrobial 219 
resistance in Canada.1,3 220 
In Canada, penicillin-resistant and MDR S. pneumoniae were rarely isolated (<5%) prior 221 
to 1990.23,24  From the 1990s to 2000, rates of penicillin-non-susceptibility in invasive isolates of 222 
pneumococci in Canada increased significantly to as high as 30% of isolates in some studies.23,25-223 
29  The introduction of PCV-7 did not have an effect on the prevalence of fluoroquinolone 224 
(levofloxacin, moxifloxacin) resistance in pneumococci as resistance to respiratory 225 
fluoroquinolones has not been associated with clonal spread and remained at very low levels 226 
(<2%) from 1998 to 2009.30  However, in the same study, fluoroquinolone resistance was 227 
associated with living in central or eastern Canada, patient age >64 years, respiratory tract 228 
isolate, hospitals with greater numbers of beds, and isolates with penicillin MICs >1 mg/L.30  In 229 
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the Canadian province of Alberta, from 2000 to 2006, overall, PCV-7 serotypes decreased 61% 230 
accompanied by a significant decline in non-susceptibility of S. pneumoniae isolates to penicillin 231 
from 14% in 2000 to 4.6% in 2006; non-susceptibility to erythromycin also decreased from 8.8% 232 
(2000) to 5.8% (2006).3  Bettinger et al. showed a decrease in vaccine serotypes from 2000 to 233 
2007 but no decrease in the proportion of invasive pneumococcal isolates that were penicillin-234 
resistant and ceftriaxone/cefotaxime-resistant.1  The ABC Surveillance Program in the USA 235 
determined the rates of IPD caused by antibiotic non-susceptible pneumococci for the regions 236 
surveyed; rates of penicillin-non-susceptible S. pneumoniae dropped from a high of 6.3/100 000 237 
in 1999 to 2.7/100 000 in 2004 (a drop of 57%).31  The greatest effect was seen in children <2 238 
years of age with a decrease in penicillin-non-susceptible S. pneumoniae of 81%.32  Demczuk et 239 
al. noted no significant changes in antimicrobial resistance rates between isolates collected 240 
during 2011 and those collected in 2012 despite a concurrent decrease in relative proportions of 241 
the generally resistant serotype 19A; they noted higher resistance rates for PCV-13 serotypes 242 
than for non-PCV-13 serotypes for the majority of tested antimicrobial agents and that the 243 
highest rates of resistance were to clarithromycin (23.3%) and penicillin using intravenous 244 
meningitis breakpoints (12.4%) while resistance was lower for clindamycin (8%) and 245 
trimethoprim/sulfamethoxazole (6%).7 246 
The primary limitation of this study is the underrepresentation of British Columbia and 247 
Alberta, two Canadian provinces who do not participate in the SAVE study.  The regional 248 
analyses may be affected by the limited representation of data from the Western provinces. 249 
S. pneumoniae is a remarkably adaptable pathogen as demonstrated by the emergence of 250 
replacement serotypes following PCV-7 and PCV-13 introduction.  The isolates tested in the 251 
current study were from 2011-2015, following the introduction of PCV-13 in Canada and 252 
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included both PCV-13 and non-PCV-13 serotypes.16  The recent report by Olarte et al. of 253 
increasing incidence of MDR serotype 35B disease underscores the limitations of pneumococcal 254 
vaccines that target the polysaccharide capsule.32  Clearly, vaccination, and replacement 255 
serotypes influence the in vitro susceptibilities of invasive S. pneumoniae in Canada, and 256 
elsewhere.  We conclude that in vitro susceptibilities of invasive isolates of S. pneumoniae 257 
increased from 2011 to 2015 for penicillin, clindamycin and ceftriaxone and that isolates with a 258 
MDR phenotype decreased over the same time.  Antimicrobial resistance rates were generally 259 
not associated with patient gender but were associated with patient age, specimen source, 260 
geographic location in Canada, and concurrent resistance to penicillin or clarithromycin for some 261 
agents.  Our observations are certainly the result of conjugate pneumococcal vaccine use in 262 
Canada and demonstrate that vaccination may serve as one approach to lowering antimicrobial 263 
resistance among invasive isolates of S. pneumoniae.  However, appropriate use of antimicrobial 264 
agents and ongoing surveillance are required to carefully monitor resistance trends by both 265 
categorical results and MIC distributions.  Equally important is careful analysis of surveillance 266 
data in terms of factors associated with resistance and other associated trends, so that resistance 267 
and susceptibility and their consequences are neither over- nor under-estimated.  Such analyses 268 
must be performed at national, regional, and institutional levels to guide physicians sufficiently 269 
in their selection of empiric therapies for patients.  To enhance the protection provided by the 270 
pneumococcal conjugate vaccines, new formulations need to continue to be developed as 271 
antimicrobial-resistant replacement serotypes continue to emerge.  272 
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Table 1. Annual antimicrobial susceptibility testing results for 14 antimicrobial agents tested against invasive isolates of S. pneumoniae  as part of the SAVE 
study from 2011 to 2015 
 
 
Yeara  
2011 2012 2013 2014 2015  
Antimicrobial agent Percent susceptible/percent resistant/MIC90 (mg/L) Pb 
Penicillin (IV, nonmeningitis) 97.3/0/0.12 98.1/0.1/0.12 99.0/0.1/0.12 99.1/0.1/0.06 99.0/0/0.12 0.001 
Penicillin (IV, meningitis) 86.3/13.7/0.12 89.1/10.9/0.12 89.9/10.1/0.12 91.0/9.0/0.06 89.5/10.5/0.12 0.017 
Penicillin (oral, penicillin V) 86.3/4.2/0.12 89.1/3.1/0.12 89.9/3.5/0.12 91.0/2.1/0.06 89.5/3.0/0.12 0.017 
Ceftriaxone (nonmeningitis) 98.6/0.2/≤0.12 99.2/0.2/≤0.12 99.3/0.2/≤0.12 99.8/0.1/≤0.12 99.7/0/≤0.12 0.002 
Ceftriaxone (meningitis) 95.8/1.4/≤0.12 96.5/0.8/≤0.12 96.5/0.7/≤0.12 97.6/0.2/≤0.12 97.3/0.3/≤0.12 0.050 
Cefuroxime (parenteral) 94.7/5.1/≤0.25 95.7/4.1/≤0.25 94.2/4.9/≤0.25 94.7/5.1/≤0.25 94.0/5.5/≤0.25 0.487 
Cefuroxime (oral) 94.9/4.8/≤0.25 95.9/3.7/≤0.25 95.1/3.7/≤0.25 94.9/3.7/≤0.25 94.5/4.1/≤0.25 0.721 
Clarithromycin 76.8/22.5/8 74.2/23.7/4 73.1/25.1/4 76.6/22.2/2 74.9/23.1/2 0.282 
Clindamycin 90.7/8.9/≤0.12 93.6/6.3/≤0.12 93.3/5.8/≤0.12 94.9/4.6/≤0.12 93.8/6.0/≤0.12 0.004 
Telithromycin 99.9/0/0.12 100/0/0.12 100/0/0.12 100/0/0.12 100/0/0.12 1 
Levofloxacin 99.6/0.4/1 99.3/0.6/1 99.4/0.5/1 99.0/0.9/1 99.7/0.3/1 0.762 
Moxifloxacin 99.6/0.2/0.25 99.3/0.4/0.25 99.5/0/0.25 99.1/0.8/0.25 99.7/0.1/0.12 1 
Linezolid 100/0/1 100/0/2 100/0/2 100/0/1 100/0/1 1 
Trimethoprim/sulfamethoxazole 87.2/5.8/1 88.1/5.7/1 86.2/7.6/1 89.3/5.9/1 87.4/6.3/1 0.904 
Doxycycline 88.5/10.9/2 89.2/10.2/1 89.4/9.8/0.5 91.1/8.0/≤0.25 90.2/8.7/≤0.25 0.175 
Tigecycline 100/0/0.03 100/0/0.03 100/0/0.03 100/0/0.03 100/0/0.03 1 
Chloramphenicol 99.0/1.0/4 97.7/2.3/4 99.0/1.0/4 96.8/3.2/4 99.0/1.0/4 1 
Vancomycin 100/0/0.5 100/0/0.5 100/0/0.25 100/0/0.25 100/0/0.25 1 
a A total of 6001 isolates of S. pneumoniae were available for antimicrobial susceptibility testing from 2001 to 2015.  The number of isolates tested per year was 
1362 isolates in 2011, 1230 isolates in 2012, 1099 isolates in 2013, 1159 isolates in 2014, and 1151 isolates in 2015. 
bP values generated by comparing antimicrobial susceptibility rates for 2011 versus 2015. 
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Table 2. Resistance to one or more antimicrobial agents among invasive isolates of S. pneumoniae in the SAVE study from 2011 to 2015 (cumulative data) 
 
  Percent of isolates (n) resistant to the indicated antimicrobial agent 
Number of 
antimicrobial 
agents to which 
isolates were 
resistanta 
% of total 
isolates 
tested (n)b 
Penicillin Clarithromycin Clindamycin Doxycycline Levofloxacin SXTc Chloramphenicol 
0 71.5 (4289) - - - - - - - 
1 17.7 (1064) 0.6 (6) 77.2 (821) 0.3 (3) 8.5 (90) 2.0 (21) 9.6 (102) 2.0 (21) 
2 4.6 (276) 6.2 (17) 76.1 (210) 18.5 (51) 47.5 (131) 1.4 (4) 34.1 (94) 16.3 (45) 
3d,e 3.1 (184) 9.2 (17) 96.7 (178) 84.8 (156) 91.3 (168) 1.1 (2) 12.5 (23) 4.3 (8) 
4d,e 1.1 (64) 46.9 (30) 100 (64) 79.7 (51) 96.9 (62) 4.7 (3) 51.6 (33) 20.3 (13) 
5d,e 1.9 (115) 98.3 (113) 100 (115) 99.1 (114) 100 (115) 0.9 (1) 97.4 (112) 4.3 (5) 
6d,e 0.1 (8) 100 (8) 100 (8) 100 (8) 100 (8) 12.5 (1) 100 (8) 87.5 (7) 
7d,e <0.1 (1) 100 (1) 100 (1) 100 (1) 100 (1) 100 (1) 100 (1) 100 (1) 
a The antimicrobial agents used in this analysis were selected as antimicrobial class markers: penicillin (oral MIC breakpoints), clarithromycin, clindamycin, 
doxycycline, levofloxacin, trimethoprim/sulfamethoxazole, and chloramphenicol. 
b A total of 6001 isolates of S. pneumoniae were available for antimicrobial susceptibility testing from 2001 to 2015. 
c SXT, trimethoprim/sulfamethoxazole. 
d MDR was defined as concurrent resistance to three or more of the seven antimicrobial classes analyzed; 6.2% (372/6001) of all isolates from 2011 to 2015 were 
MDR. 
e The percent prevalence of MDR isolates (n/total n) by year was 8.5% (116/1362) in 2011, 6.8 % (83/1230) in 2012, 5.8% (64/1099) in 2013, 3.9% (45/1159) in 
2014, 5.6% (64/1151) in 2015 (P <0.001).  
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Table 3. Relative associations between resistance to sixa antimicrobial agents and patient demographic/isolate factors among invasive isolates of S. pneumoniae in the SAVE study from 2011 to 2015 (cumulative data) 
 
Patient demographic/isolate factor 
n of 
isolates 
associated 
with risk 
factor 
Penicillin Clarithromycin Doxycycline SXTa Chloramphenicol Clindamycin 
n (%) of 
resistant 
isolates 
Pb 
n (%) of 
resistant 
isolates 
P 
n (%) of 
resistant 
isolates 
P 
n (%) of 
resistant 
isolates 
P 
n (%) of 
resistant 
isolates 
P 
n (%) of 
resistant 
isolates 
P 
All isolates 6001 192 (3.2%) – 1397 (23.3%) – 575 (9.6%) – 373 (6.2%) – 100 (1.7%) – 384 (6.4%) – 
Patient age, yearsc   0.057  0.307  0.101  0.335  0.026  0.004 
     <18 851 37 (4.3%)  208 (24.4%)  81 (9.5%)  62 (7.3%)  5 (0.6%)  65 (7.6%)  
     18-64 2788 76 (2.7%)  627 (22.5%)  245 (8.8%)  165 (5.9%)  51 (1.8%)  148 (5.3%)  
     >64 2231 73 (3.3%)  537 (24.1%)  236 (10.6%)  135 (6.1%)  43 (1.9%)  164 (7.4%)  
Patient genderd   0.075  0.041  0.669  0.432  0.627  0.775 
     Female 2660 97 (3.6%)  660 (24.8%)  262 (9.8%)  158 (5.9%)  47 (1.8%)  175 (6.6%)  
     Male 3121 88 (2.8%)  703 (22.5%)  297 (9.5%)  201 (6.4%)  50 (1.6%)  199 (6.4%)  
Invasive specimen source   <0.001  0.154  <0.001  0.004  0.950  <0.001 
     Blood 5448 155 (2.8%)  1257 (23.1%)  498 (9.1%)  322 (5.9%)  90 (1.7%)  326 (6.0%)  
     Cerebrospinal fluid 235 9 (3.8%)  52 (22.1%)  27 (11.5%)  18 (7.7%)  4 (1.7%)  22 (9.4%)  
     Other sterile body fluidse 318 28 (8.8%)  88 (27.7%)  50 (15.7%)  33 (10.4%)  6 (1.9%)  36 (11.3%)  
Geographic regionf   <0.001  0.051  <0.001  0.003  <0.001  0.077 
     Western Canada 1321 53 (4.0%)  336 (25.4%)  89 (6.7%)  102 (7.7%)  12 (0.9%)  67 (5.1%)  
     Central Canada 3952 102 (2.6%)  883 (22.3%)  411 (10.4%)  215 (5.4%)  84 (2.1%)  270 (6.8%)  
     Eastern Canada 728 37 (5.1%)  178 (24.5%)  75 (10.3%)  56 (7.7%)  4 (0.5%)  47 (6.5%)  
Penicillin MIC interpretative categoryg   –  <0.001  <0.001  <0.001  <0.001  <0.001 
     Susceptible (≤0.06 mg/L) 5345 –  991 (18.5%)  204 (3.8%)  131 (2.5%)  85 (1.6%)  115 (2.2%)  
     Intermediate (0.12-1 mg/L) 464 –  233 (50.2%)  213 (45.9%)  86 (18.5%)  4 (0.9%)  130 (28.0%)  
     Resistant (≥2 mg/L) 192 –  173 (90.1%)  158 (82.3%)  156 (81.2%)  11 (5.7%)  139 (72.4%)  
Clarithromycin MIC interpretative category   <0.001  –  <0.001  <0.001  <0.001  <0.001 
     Susceptible (≤0.25 mg/L) 4512 16 (0.4%)  –  124 (2.7%)  119 (2.6%)  59 (1.3%)  4 (0.1%)  
     Intermediate (0.5 mg/L) 92 3 (3.3%)  –  28 (30.4%)  10 (10.9%)  1 (1.1%)  5 (5.4%)  
     Resistant (≥1 mg/L) 1397 173 (12.4%)  –  423 (30.3%)  244 (17.5%)  40 (2.9%)  375 (26.8%)  
a SXT, trimethoprim/sulfamethoxazole. 
b The Chi-square test identified significant differences between individual patient demographic/isolate factors within a group of factors but does not specify the identity of the difference within the group of factors. 
c There were 131 isolates with unknown patient age. 
d There were 220 isolates with unknown patient gender. 
e Other sterile body fluids were comprised of pleural fluid (n=123), synovial fluid (n=38), peritoneal fluid (n=12), pericardial fluid (n=4), abscess (n=3), other sterile site/source not given (n=138). 
f Western Canada included isolates from Manitoba and Saskatchewan, Central Canada included isolates from Ontario and Quebec, and Eastern Canada included isolates from Nova Scotia, New Brunswick, Prince Edward Island, 
and Newfoundland and Labrador. 
g Penicillin (oral penicillin V) MIC breakpoints were used. 
